Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
19 May 2022
Historique:
received: 29 11 2021
accepted: 22 04 2022
pubmed: 7 5 2022
medline: 24 5 2022
entrez: 6 5 2022
Statut: epublish

Résumé

Incretins are known to influence lipid metabolism in the intestine when administered as pharmacologic agents. The aggregate influence of endogenous incretins on chylomicron production and clearance is less clear, particularly in light of opposing effects of co-secreted hormones. Here, we tested the hypothesis that physiological levels of incretins may impact on production or clearances rates of chylomicrons and VLDL. A group of 22 overweight/obese men was studied to determine associations between plasma levels of glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) after a fat-rich meal and the production and clearance rates of apoB48- and apoB100-containing triglyceride-rich lipoproteins. Subjects were stratified by above- and below-median incretin response (area under the curve). Stratification yielded subgroups that differed about two-fold in incretin response. There were neither differences in apoB48 production rates in chylomicrons or VLDL fractions nor in apoB100 or triglyceride kinetics in VLDL between men with above- vs below-median incretin responses. The men with above-median GLP-1 and GLP-2 responses exhibited higher postprandial plasma and chylomicron triglyceride levels, but this could not be related to altered kinetic parameters. No differences were found between incretin response subgroups and particle clearance rates. We found no evidence for a regulatory effect of endogenous incretins on contemporaneous chylomicron or VLDL metabolism following a standardised fat-rich meal. The actions of incretins at pharmacological doses may not be reflected at physiological levels of these hormones.

Identifiants

pubmed: 35521766
doi: 10.1530/EJE-21-1187
doi:

Substances chimiques

Apolipoprotein B-48 0
Chylomicrons 0
Incretins 0
Lipoproteins 0
Triglycerides 0
Gastric Inhibitory Polypeptide 59392-49-3
Glucagon-Like Peptide 1 89750-14-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-84

Auteurs

Marja-Riitta Taskinen (MR)

Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.

Niina Matikainen (N)

Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.
Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland.

Elias Björnson (E)

Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

Sanni Söderlund (S)

Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.
Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland.

Mari Ainola (M)

Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.

Antti Hakkarainen (A)

HUS Medical Imaging Center, Radiology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.

Nina Lundbom (N)

HUS Medical Imaging Center, Radiology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.

Carina Sihlbom (C)

Proteomics Facility, University of Gothenburg, Gothenburg, Sweden.

Annika Thorsell (A)

Proteomics Facility, University of Gothenburg, Gothenburg, Sweden.

Linda Andersson (L)

Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

Martin Adiels (M)

Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

Bolette Hartmann (B)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Carolyn F Deacon (CF)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
School of Biomedical Sciences, Ulster University, Coleraine, UK.

Jens J Holst (JJ)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Chris J Packard (CJ)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Jan Borén (J)

Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH